SI2585470T1 - Novi fuzirani derivati pirimidina za inhibicijo aktivnosti tirozin kinaze - Google Patents

Novi fuzirani derivati pirimidina za inhibicijo aktivnosti tirozin kinaze

Info

Publication number: SI2585470T1
Authority: SI; Slovenia
Prior art keywords: inhibition; tyrosine kinase; kinase activity; pyrimidine derivatives; fused pyrimidine
Prior art date: 2010-06-23

Application number

SI201131094A

Other languages

English (en)

Inventor

Mi Young Cha

Seok Jong Kang

Mi Ra Kim

Ju Yeon Lee

Ji Young Jeon

Myoung Gi Jo

Eun Joo Kwak

Kwang Ok Lee

Tae Hee Ha

Kwee Hyun Suh

Maeng Sup Kim

Original Assignee

Hanmi Science Co., Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-06-23

Filing date

2011-06-20

Publication date

2017-03-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45371929&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2585470(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-06-20 Application filed by Hanmi Science Co., Ltd. filed Critical Hanmi Science Co., Ltd.

2017-03-31 Publication of SI2585470T1 publication Critical patent/SI2585470T1/sl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3834—Aromatic acids (P-C aromatic linkage)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/09—Geometrical isomers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Immunology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Hospice & Palliative Care (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Orthopedic Medicine & Surgery (AREA)
Transplantation (AREA)
Otolaryngology (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)

SI201131094A 2010-06-23 2011-06-20 Novi fuzirani derivati pirimidina za inhibicijo aktivnosti tirozin kinaze SI2585470T1 (sl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
KR20100059686		2010-06-23
PCT/KR2011/004482 WO2011162515A2 (en)	2010-06-23	2011-06-20	Novel fused pyrimidine derivatives for inhd3ition of tyrosine kinase activity
EP11798350.2A EP2585470B1 (en)	2010-06-23	2011-06-20	Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity

Publications (1)

Publication Number	Publication Date
SI2585470T1 true SI2585470T1 (sl)	2017-03-31

Family

ID=45371929

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SI201131094A SI2585470T1 (sl)	2010-06-23	2011-06-20	Novi fuzirani derivati pirimidina za inhibicijo aktivnosti tirozin kinaze
SI201131644T SI2975042T1 (sl)	2010-06-23	2011-06-20	Novi fuzirani derivati pirimidina za inhibicijo aktivnosti tirozin kinaze

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SI201131644T SI2975042T1 (sl)	2010-06-23	2011-06-20	Novi fuzirani derivati pirimidina za inhibicijo aktivnosti tirozin kinaze

Country Status (32)

Country	Link
US (4)	USRE46511E1 (sl)
EP (2)	EP2975042B1 (sl)
JP (2)	JP5834347B2 (sl)
KR (2)	KR101587506B1 (sl)
CN (2)	CN105061438B (sl)
AR (2)	AR081978A1 (sl)
AU (1)	AU2011269989B2 (sl)
BR (2)	BR112012033253A2 (sl)
CA (1)	CA2803056C (sl)
CY (1)	CY1118750T1 (sl)
DK (2)	DK2975042T3 (sl)
ES (2)	ES2622138T3 (sl)
HK (1)	HK1211575A1 (sl)
HR (2)	HRP20170456T1 (sl)
HU (2)	HUE042165T2 (sl)
IL (2)	IL223689A (sl)
LT (2)	LT2585470T (sl)
MX (2)	MX2012014601A (sl)
MY (2)	MY162132A (sl)
NZ (2)	NZ627709A (sl)
PH (1)	PH12012502431B1 (sl)
PL (2)	PL2585470T3 (sl)
PT (2)	PT2975042T (sl)
RS (2)	RS55783B1 (sl)
RU (2)	RU2598852C2 (sl)
SG (1)	SG186378A1 (sl)
SI (2)	SI2585470T1 (sl)
TR (1)	TR201821217T4 (sl)
TW (2)	TWI528962B (sl)
UA (2)	UA111272C2 (sl)
WO (1)	WO2011162515A2 (sl)
ZA (1)	ZA201209742B (sl)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL2529622T3 (pl)	2006-09-22	2018-07-31	Pharmacyclics Llc	Inhibitory kinazy tyrozynowej brutona
US8809273B2 (en)	2007-03-28	2014-08-19	Pharmacyclics, Inc.	Inhibitors of Bruton's tyrosine kinase
KR101860057B1 (ko)	2008-05-21	2018-05-21	어리어드 파마슈티칼스, 인코포레이티드	키나아제 억제제로서 포스포러스 유도체
US9273077B2 (en)	2008-05-21	2016-03-01	Ariad Pharmaceuticals, Inc.	Phosphorus derivatives as kinase inhibitors
CN102159214A (zh)	2008-07-16	2011-08-17	药品循环公司	用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
CA3022256C (en)	2010-06-03	2021-03-30	Pharmacyclics Llc	The use of inhibitors of bruton's tyrosine kinase (btk)
PL2585470T3 (pl) *	2010-06-23	2017-07-31	Hanmi Science Co., Ltd.	Nowe sprzężone pochodne pirymidyny do hamowania aktywności kinazy tyrozynowej
KR20140005882A (ko) *	2010-10-08	2014-01-15	애브비 인코포레이티드	푸로[3,2-ｄ]피리미딘 화합물
JP2013539795A (ja) *	2010-10-14	2013-10-28	アリアド・ファーマシューティカルズ・インコーポレイテッド	Ｅｇｆｒ発動性がんの細胞増殖の阻害方法
CA2832504C (en)	2011-05-04	2019-10-01	Ariad Pharmaceuticals, Inc.	Compounds for inhibiting cell proliferation in egfr-driven cancers
AU2012283775A1 (en)	2011-07-13	2014-01-23	Pharmacyclics Llc	Inhibitors of Bruton's tyrosine kinase
PT3333161T (pt)	2011-07-27	2020-05-18	Astrazeneca Ab	Derivados de 2-(2,4,5-anilino-substituídos)pirimidina como moduladores do egfr úteis para o tratamento do cancro
KR20130076046A (ko) *	2011-12-28	2013-07-08	한미약품 주식회사	타이로신 카이네이즈 억제 활성을 갖는 신규 이미다조피리딘 유도체
US8377946B1 (en)	2011-12-30	2013-02-19	Pharmacyclics, Inc.	Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US9464089B2 (en)	2012-01-13	2016-10-11	Acea Biosciences Inc.	Heterocyclic compounds and uses thereof
US9586965B2 (en)	2012-01-13	2017-03-07	Acea Biosciences Inc.	Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases
AU2013207712B2 (en)	2012-01-13	2017-08-31	Acea Biosciences Inc.	Heterocyclic compounds and uses as anticancer agents.
US9034885B2 (en)	2012-01-13	2015-05-19	Acea Biosciences Inc.	EGFR modulators and uses thereof
KR20130091464A (ko) *	2012-02-08	2013-08-19	한미약품 주식회사	타이로신 카이네이즈 억제 활성을 갖는 트리아졸로피리딘 유도체
KR101660145B1 (ko) *	2012-02-23	2016-09-26	다이호야쿠힌고교 가부시키가이샤	퀴놀릴피롤로피리미딜 축합환 화합물 또는 그의 염
AU2013204563B2 (en) *	2012-05-05	2016-05-19	Takeda Pharmaceutical Company Limited	Compounds for inhibiting cell proliferation in EGFR-driven cancers
JP6236071B2 (ja)	2012-06-04	2017-11-22	ファーマサイクリックスエルエルシー	ブルトン型チロシンキナーゼ阻害剤の結晶形態
CN104520291A (zh) *	2012-06-06	2015-04-15	Irm责任有限公司	用于调节egfr活性的化合物和组合物
WO2014018567A1 (en)	2012-07-24	2014-01-30	Pharmacyclics, Inc.	Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
AU2013344656A1 (en)	2012-11-15	2015-06-04	Pharmacyclics Llc	Pyrrolopyrimidine compounds as kinase inhibitors
CA2898274A1 (en)	2013-02-22	2014-08-28	Taiho Pharmaceutical Co., Ltd.	Method for producing tricyclic compound, and tricyclic compound capable of being produced by said production method
US9611283B1 (en)	2013-04-10	2017-04-04	Ariad Pharmaceuticals, Inc.	Methods for inhibiting cell proliferation in ALK-driven cancers
CN103242341B (zh) *	2013-04-19	2015-12-09	中国科学院广州生物医药与健康研究院	噻吩并2，4取代嘧啶类化合物及其药物组合物与应用
WO2014175370A1 (ja) *	2013-04-25	2014-10-30	塩野義製薬株式会社	ピロリジン誘導体およびそれらを含有する医薬組成物
EA028756B1 (ru)	2013-04-25	2017-12-29	Бэйджин, Лтд.	Конденсированные гетероциклические соединения в качестве ингибиторов протеинкиназы
AU2014287016B2 (en) *	2013-07-11	2018-11-01	Acea Biosciences Inc.	Pyrimidine derivatives as kinase inhibitors
AR097204A1 (es)	2013-08-02	2016-02-24	Pharmacyclics Inc	Métodos de tratamiento de tumores sólidos
EP2832358A1 (en)	2013-08-02	2015-02-04	Bionsil S.r.l.	Pharmaceutical kit for use in the treatment of colon and colorectal cancer
EP3033079B1 (en)	2013-08-12	2018-10-31	Pharmacyclics LLC	Methods for the treatment of her2 amplified cancer
CN107090041B (zh)	2013-09-13	2018-11-16	百济神州有限公司	抗pd1抗体及其作为治疗剂与诊断剂的用途
BR112016005881A2 (pt) *	2013-09-18	2017-09-12	Beijing Hanmi Pharmaceutical Co Ltd	composto, composição farmacêutica e uso do composto
EP3052486A1 (en)	2013-09-30	2016-08-10	Pharmacyclics LLC	Inhibitors of bruton's tyrosine kinase
FR3015483B1 (fr) *	2013-12-23	2016-01-01	Servier Lab	Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2015143400A1 (en)	2014-03-20	2015-09-24	Pharmacyclics, Inc.	Phospholipase c gamma 2 and resistance associated mutations
WO2015148904A1 (en) *	2014-03-28	2015-10-01	Driver Group	Methods for predicting egfr tyrosine kinase inhibitor efficacy
EP3125920B1 (en)	2014-04-04	2020-12-23	Del Mar Pharmaceuticals	Dianhydrogalactitol, diacetyldianhydrogalactitol or dibromodulcitol to treat non-small-cell carcinoma of the lung and ovarian cancer
PT3137470T (pt)	2014-05-01	2021-06-24	Novartis Ag	Compostos e composições como agonistas do recetor tipo toll 7
SG11201608299TA (en)	2014-05-01	2016-11-29	Novartis Ag	Compounds and compositions as toll-like receptor 7 agonists
SG11201609837WA (en) *	2014-05-28	2016-12-29	Astellas Pharma Inc	Pharmaceutical composition comprising pyrazine carboxamide compound as active ingredient
CN106604742B (zh)	2014-07-03	2019-01-11	百济神州有限公司	抗pd-l1抗体及其作为治疗剂及诊断剂的用途
EP2974729A1 (en)	2014-07-17	2016-01-20	Abivax	Quinoline derivatives for use in the treatment of inflammatory diseases
AU2015296215A1 (en)	2014-08-01	2017-03-23	Pharmacyclics Llc	Inhibitors of bruton's tyrosine kinase
WO2016020901A1 (en)	2014-08-07	2016-02-11	Acerta Pharma B.V.	Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate
BR112017002231A2 (pt)	2014-08-07	2018-07-17	Pharmacyclics Llc	novas formulações de um inibidor de tirosina cinase de bruton
KR20160082062A (ko)	2014-12-30	2016-07-08	한미약품 주식회사	싸이옥소 퓨로피리미디논 유도체의 제조방법 및 이에 사용되는 중간체
EP3224257B1 (en)	2014-12-30	2019-10-16	Hanmi Pharm. Co., Ltd.	Novel method for preparing thienopyrimidine compound and intermediates used therein
CN105837572B (zh) *	2015-02-02	2019-04-19	四川大学	N-取代苯基酰胺衍生物及其制备方法和用途
RU2572709C1 (ru) *	2015-03-03	2016-01-20	Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации	Способ коррекции структурно-функциональных нарушений артериального русла у больных ревматоидным артритом
IL315294A (en)	2015-03-03	2024-10-01	Pharmacyclics Llc	Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
CA2988896C (en)	2015-04-29	2023-08-15	Guangdong Zhongsheng Pharmaceutical Co., Ltd.	Fused-ring or tricyclic aryl pyrimidine compound used as kinase inhibitor
EP3799873A1 (en)	2015-07-17	2021-04-07	Institut Pasteur	5-hydroxytryptamine 1b receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation
MA44909A (fr)	2015-09-15	2018-07-25	Acerta Pharma Bv	Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
CN107949388B (zh)	2015-10-09	2021-10-26	艾森医药公司	吡咯并嘧啶激酶抑制剂的药用盐、物理形态和组合物及其制备方法
MA44334A (fr)	2015-10-29	2018-09-05	Novartis Ag	Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
KR20170050453A (ko) *	2015-10-30	2017-05-11	한미약품 주식회사	싸이에노피리미딘 화합물의 신규 제조방법 및 이에 사용되는 중간체
WO2017092523A1 (zh) *	2015-12-02	2017-06-08	深圳市塔吉瑞生物医药有限公司	一种稠合嘧啶化合物及包含该化合物的组合物及其用途
WO2017096095A1 (en) *	2015-12-03	2017-06-08	Shanghai Aeon Biotech Co., Ltd.	Thieno-pyrimidine derivatives and uses thereof
AU2016362394B2 (en)	2015-12-03	2021-01-14	Zhejiang Jianfeng-Yien Biotechnology Co., Ltd.	Heterocycle compounds and uses thereof
KR20180089903A (ko) *	2015-12-31	2018-08-09	한미약품 주식회사	싸이에노피리미딘 화합물의 하이드로클로라이드 염의 결정형
EP3380482A4 (en) *	2015-12-31	2019-05-15	Hanmi Pharm. Co., Ltd.	CRYSTALLINE FORMS OF A THIENOPYRIMIDINE COMPOUND
HUE052893T2 (hu)	2016-01-13	2021-05-28	Acerta Pharma Bv	Antifolát és BTK-gátló terápiás kombinációi
US20190125751A1 (en) *	2016-05-18	2019-05-02	Boehringer Ingelheim International Gmbh	Anticancer combination therapy
KR20190003805A (ko) *	2016-05-27	2019-01-09	한미약품 주식회사	암 세포 성장을 저해하는 아민 유도체 또는 이의 약학적으로 허용가능한 염 및 저융점을 갖는 안정화제를 포함하는 약학적 조성물
PE20190811A1 (es) *	2016-06-30	2019-06-13	Dae Woong Pharma	Derivados de pirazolopirimidinas como inhibidor de quinasa
US10864203B2 (en)	2016-07-05	2020-12-15	Beigene, Ltd.	Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
JP2019524723A (ja)	2016-07-15	2019-09-05	アンスティテュ・パストゥール	皮膚および／または毛の修復のための５−ヒドロキシトリプタミン１ｂ受容体刺激剤
CN107698603B (zh) *	2016-08-09	2022-04-08	南京红云生物科技有限公司	噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用
TWI865873B (zh)	2016-08-16	2024-12-11	瑞士商百濟神州瑞士有限責任公司	(s)-7-(1-丙烯醯基六氫吡啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氫吡唑並[1,5-a]嘧啶-3-甲醯胺的晶型、其製備和用途
AU2017313085B2 (en)	2016-08-19	2024-06-20	Beigene Switzerland Gmbh	Use of a combination comprising a Btk inhibitor for treating cancers
EP3515414B1 (en)	2016-09-19	2022-11-30	MEI Pharma, Inc.	Combination therapy
CN106565612B (zh) *	2016-10-25	2018-10-16	大连医科大学	二苯乙烯基嘧啶类化合物，组合物及其用途
CA3045339A1 (en)	2016-12-03	2018-06-07	Juno Therapeutics, Inc.	Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors
KR20180075228A (ko)	2016-12-26	2018-07-04	한미약품 주식회사	싸이에노피리미딘 화합물의 신규 제조방법 및 중간체
WO2018134786A1 (en)	2017-01-19	2018-07-26	Acerta Pharma B.V.	Compositions and methods for the assessment of drug target occupancy for bruton's tyrosine kinase
US11555038B2 (en)	2017-01-25	2023-01-17	Beigene, Ltd.	Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
WO2018139883A1 (ko) *	2017-01-26	2018-08-02	부광약품 주식회사	다중 표적 키나아제 저해제로서 융합피리미딘 유도체
CN106831814B (zh) *	2017-02-15	2018-11-23	山东大学	一种噻吩并[3,2-d]嘧啶类HIV-1逆转录酶抑制剂及其制备方法和应用
CN106916112B (zh) *	2017-03-02	2019-12-20	四川海思科制药有限公司	嘧啶衍生物及其制备方法和在医药上的应用
CN106866699B (zh) *	2017-03-29	2019-03-08	山东大学	一种二芳基噻吩并嘧啶类hiv-1逆转录酶抑制剂及其制备方法和应用
US11498922B2 (en)	2017-04-07	2022-11-15	ACEA Therapeutics, Inc.	Pharmaceutical composition comprising N-(3-((2-((3-fluoro-4-(4-methylpiperazin-1-yl phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenylacrylamide
CN108727382B (zh) *	2017-04-19	2022-07-19	华东理工大学	作为btk抑制剂的杂环化合物及其应用
EP3645569A4 (en)	2017-06-26	2021-03-24	BeiGene, Ltd.	IMMUNOTHERAPY FOR LIVER CELL CARCINOMA
CN109206435B (zh) *	2017-06-29	2020-09-08	中国医药研究开发中心有限公司	噻吩并[3,2-d]嘧啶类化合物及其制备方法和医药用途
WO2019034009A1 (en)	2017-08-12	2019-02-21	Beigene, Ltd.	BTK INHIBITOR WITH ENHANCED DOUBLE SELECTIVITY
WO2019034153A1 (zh) *	2017-08-18	2019-02-21	北京韩美药品有限公司	一种化合物，其药物组合物及其用途及应用
CN109575045B (zh) *	2017-09-28	2021-02-12	南京红云生物科技有限公司	噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用
KR102613433B1 (ko) *	2017-10-11	2023-12-13	주식회사 대웅제약	신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물
AU2018367909B2 (en)	2017-11-17	2022-03-10	Cellix Bio Private Limited	Compositions and methods for the treatment of eye disorders
US11786529B2 (en)	2017-11-29	2023-10-17	Beigene Switzerland Gmbh	Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
CN109627263B (zh)	2017-12-21	2022-05-20	深圳市塔吉瑞生物医药有限公司	用于抑制激酶活性的二苯氨基嘧啶类化合物
LT3733673T (lt)	2017-12-28	2022-08-10	Daewoong Pharmaceutical Co., Ltd.	Oksi-fluorpiperidino darinys, kaip kinazės inhibitorius
KR102577241B1 (ko) *	2017-12-28	2023-09-11	주식회사 대웅제약	카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체
KR102577242B1 (ko)	2017-12-28	2023-09-11	주식회사 대웅제약	카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
CN111989322B (zh)	2018-04-23	2024-04-02	细胞基因公司	取代的4-氨基异吲哚啉-1,3-二酮化合物以及它们用于治疗淋巴瘤的用途
WO2019208805A1 (ja)	2018-04-27	2019-10-31	小野薬品工業株式会社	Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤
KR101954370B1 (ko) *	2018-07-25	2019-03-05	한미약품 주식회사	피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
PE20210406A1 (es)	2018-07-25	2021-03-02	Novartis Ag	Inhibidores de inflamasoma nlrp3
CA3111126A1 (en)	2018-08-31	2020-03-05	Stichting Katholieke Universiteit	Synergistic combinations of amino acid depletion agent sensitizers (aadas) and amino acid depletion agents (aada), and therapeutic methods of use thereof
CN109265469A (zh) *	2018-11-12	2019-01-25	大连医科大学附属第医院	嘧啶并噻唑类杂环化合物，组合物及其治疗淋巴细胞白血病的用途
EP3669873A1 (en)	2018-12-20	2020-06-24	Abivax	Quinoline derivatives for use ine the traeatment of inflammation diseases
CN111747950B (zh) *	2019-03-29	2024-01-23	深圳福沃药业有限公司	用于治疗癌症的嘧啶衍生物
KR20200114776A (ko) *	2019-03-29	2020-10-07	한미약품 주식회사	퓨로피리미딘 화합물의 산 부가염의 결정형
CN111909101B (zh) *	2019-05-10	2022-07-19	浙江大学	一种egfr激酶抑制剂及其在制备抗癌药物方面的应用
AR119731A1 (es)	2019-05-17	2022-01-05	Novartis Ag	Inhibidores del inflamasoma nlrp3
CA3133004A1 (en) *	2019-05-31	2020-12-03	Sichuan Haisco Pharmaceutical Co., Ltd.	Btk inhibitor ring derivative, preparation method therefor and pharmaceutical application thereof
TWI856111B (zh)	2019-06-10	2024-09-21	瑞士商百濟神州瑞士有限責任公司	一種含有布魯頓氏酪胺酸激酶抑制劑的口服固體錠劑及其製備方法
CA3139969A1 (en) *	2019-06-20	2020-12-24	Dana-Farber Cancer Institute, Inc.	Small molecule inhibitors of src tyrosine kinase
CN110372529B (zh) *	2019-08-08	2022-05-24	黄河水利职业技术学院	N-[(3,4,5-三氟)苯基]丙烯酰胺及其制备方法
CN110511994B (zh) *	2019-09-09	2023-05-26	中南大学湘雅二医院	miRNA-4769-3p及其同源物的应用
CN115087655A (zh) *	2019-12-20	2022-09-20	辉瑞公司	苯并咪唑衍生物
US11345681B1 (en)	2020-06-05	2022-05-31	Kinnate Biopharma Inc.	Inhibitors of fibroblast growth factor receptor kinases
CN116239603A (zh) *	2020-06-20	2023-06-09	江西科技师范大学	一种2-氨基嘧啶杂环类化合物及其应用
BR112023002031A2 (pt)	2020-08-14	2023-03-07	Novartis Ag	Derivados de espiropiperidinila substituídos por heteroarila e usos farmacêuticos dos mesmos
AU2021371697B2 (en) *	2020-10-29	2024-10-24	Suzhou Yabao Pharmaceutical R&D Co., Ltd.	Substituted diarylamine compound, pharmaceutical composition thereof, preparation method therefor, and use thereof
US20240216330A1 (en)	2021-04-02	2024-07-04	Biogen Ma Inc.	Combination treatment methods of multiple sclerosis
US11786531B1 (en)	2022-06-08	2023-10-17	Beigene Switzerland Gmbh	Methods of treating B-cell proliferative disorder
TW202406550A (zh)	2022-08-03	2024-02-16	瑞士商諾華公司	Ｎｌｒｐ３炎性小體抑制劑
WO2024123126A1 (ko) *	2022-12-09	2024-06-13	재단법인대구경북과학기술원	올무티닙을 유효성분으로 포함하는 신경염증 또는 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HRP970371A2 (en)	1996-07-13	1998-08-31	Kathryn Jane Smith	Heterocyclic compounds
AU2004267061A1 (en) *	2003-08-19	2005-03-03	Wyeth Holdings Corporation	Process for the preparation of 4-amino-3-quinolinecarbonitriles
EP1979329A2 (en)	2006-01-30	2008-10-15	Exelixis, Inc.	4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and methods of use
JP2008013527A (ja)	2006-07-10	2008-01-24	Sankyo Co Ltd	チエノ［３，２−ｄ］ピリミジン−２，４−ジアミン誘導体
KR101507182B1 (ko) *	2006-12-07	2015-03-30	제넨테크, 인크.	포스포이노시타이드 3-키나제 억제제 화합물 및 그의 사용 방법
WO2008152394A1 (en)	2007-06-12	2008-12-18	F.Hoffmann-La Roche Ag	Pharmaceutical compounds
WO2009017838A2 (en)	2007-08-01	2009-02-05	Exelixis, Inc.	Combinations of jak-2 inhibitors and other agents
WO2009062258A1 (en) *	2007-11-15	2009-05-22	Cytopia Research Pty Ltd	N-containing heterocyclic compounds
JP5298187B2 (ja) *	2008-04-07	2013-09-25	アイアールエム・リミテッド・ライアビリティ・カンパニー	タンパク質キナーゼ阻害剤としての化合物および組成物
EP2361248B1 (en)	2008-06-27	2018-09-19	Celgene CAR LLC	Heteroaryl compounds and uses thereof
WO2010054285A2 (en) *	2008-11-10	2010-05-14	National Health Research Institutes	Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
ES2659725T3 (es) *	2009-05-05	2018-03-19	Dana-Farber Cancer Institute, Inc.	Inhibidores de EGFR y procedimiento de tratamiento de trastornos
WO2011079231A1 (en)	2009-12-23	2011-06-30	Gatekeeper Pharmaceutical, Inc.	Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
PL2585470T3 (pl) *	2010-06-23	2017-07-31	Hanmi Science Co., Ltd.	Nowe sprzężone pochodne pirymidyny do hamowania aktywności kinazy tyrozynowej
MD20140023A2 (ro) *	2011-09-22	2014-06-30	Pfizer Inc.	Derivaţi de pirolpirimidină şi purină

2011
- 2011-06-20 PL PL11798350T patent/PL2585470T3/pl unknown
- 2011-06-20 LT LTEP11798350.2T patent/LT2585470T/lt unknown
- 2011-06-20 SI SI201131094A patent/SI2585470T1/sl unknown
- 2011-06-20 RS RS20170267A patent/RS55783B1/sr unknown
- 2011-06-20 TR TR2018/21217T patent/TR201821217T4/tr unknown
- 2011-06-20 BR BR112012033253A patent/BR112012033253A2/pt not_active IP Right Cessation
- 2011-06-20 BR BR122014012788-0A patent/BR122014012788B1/pt active IP Right Grant
- 2011-06-20 MX MX2012014601A patent/MX2012014601A/es active IP Right Grant
- 2011-06-20 SI SI201131644T patent/SI2975042T1/sl unknown
- 2011-06-20 MX MX2014005025A patent/MX342164B/es unknown
- 2011-06-20 US US15/099,171 patent/USRE46511E1/en active Active
- 2011-06-20 EP EP15181011.6A patent/EP2975042B1/en active Active
- 2011-06-20 CN CN201510477438.3A patent/CN105061438B/zh active Active
- 2011-06-20 JP JP2013516501A patent/JP5834347B2/ja active Active
- 2011-06-20 RS RS20190004A patent/RS58265B1/sr unknown
- 2011-06-20 DK DK15181011.6T patent/DK2975042T3/en active
- 2011-06-20 ES ES11798350.2T patent/ES2622138T3/es active Active
- 2011-06-20 PL PL15181011T patent/PL2975042T3/pl unknown
- 2011-06-20 NZ NZ627709A patent/NZ627709A/en unknown
- 2011-06-20 HU HUE15181011A patent/HUE042165T2/hu unknown
- 2011-06-20 CA CA2803056A patent/CA2803056C/en active Active
- 2011-06-20 CN CN201180030338.6A patent/CN102947316B/zh active Active
- 2011-06-20 ES ES15181011T patent/ES2703552T3/es active Active
- 2011-06-20 PT PT15181011T patent/PT2975042T/pt unknown
- 2011-06-20 KR KR1020110059612A patent/KR101587506B1/ko active Active
- 2011-06-20 EP EP11798350.2A patent/EP2585470B1/en active Active
- 2011-06-20 UA UAA201410791A patent/UA111272C2/uk unknown
- 2011-06-20 WO PCT/KR2011/004482 patent/WO2011162515A2/en active Application Filing
- 2011-06-20 NZ NZ605988A patent/NZ605988A/en not_active IP Right Cessation
- 2011-06-20 SG SG2012092862A patent/SG186378A1/en unknown
- 2011-06-20 LT LTEP15181011.6T patent/LT2975042T/lt unknown
- 2011-06-20 DK DK11798350.2T patent/DK2585470T3/en active
- 2011-06-20 HU HUE11798350A patent/HUE032515T2/en unknown
- 2011-06-20 RU RU2014147193/04A patent/RU2598852C2/ru active
- 2011-06-20 UA UAA201300777A patent/UA108889C2/uk unknown
- 2011-06-20 RU RU2013102881/04A patent/RU2585177C2/ru not_active IP Right Cessation
- 2011-06-20 PT PT117983502T patent/PT2585470T/pt unknown
- 2011-06-20 AU AU2011269989A patent/AU2011269989B2/en not_active Ceased
- 2011-06-20 MY MYPI2012005536A patent/MY162132A/en unknown
- 2011-06-20 US US13/805,183 patent/US8957065B2/en not_active Ceased
- 2011-06-20 PH PH1/2012/502431A patent/PH12012502431B1/en unknown
- 2011-06-22 TW TW100121796A patent/TWI528962B/zh not_active IP Right Cessation
- 2011-06-22 TW TW103121058A patent/TWI513701B/zh active
- 2011-06-23 AR ARP110102172A patent/AR081978A1/es unknown
2012
- 2012-12-17 IL IL223689A patent/IL223689A/en active IP Right Grant
- 2012-12-20 MY MYPI2016002018A patent/MY174196A/en unknown
- 2012-12-21 ZA ZA2012/09742A patent/ZA201209742B/en unknown
2014
- 2014-04-09 KR KR1020140042459A patent/KR101589114B1/ko active Active
- 2014-04-23 AR ARP140101695A patent/AR096075A2/es active IP Right Grant
- 2014-04-30 IL IL232382A patent/IL232382A/en active IP Right Grant
- 2014-05-13 JP JP2014099471A patent/JP5852173B2/ja active Active
- 2014-10-23 US US14/521,766 patent/US9345719B2/en active Active
2015
- 2015-12-14 HK HK15112265.6A patent/HK1211575A1/xx unknown
2016
- 2016-04-15 US US15/099,815 patent/US20160229868A1/en not_active Abandoned
2017
- 2017-03-20 HR HRP20170456TT patent/HRP20170456T1/hr unknown
- 2017-03-20 CY CY20171100349T patent/CY1118750T1/el unknown
2019
- 2019-01-03 HR HRP20190012TT patent/HRP20190012T1/hr unknown

Also Published As

Publication number	Publication date
CA2803056A1 (en)	2011-12-29
HK1211575A1 (en)	2016-05-27
ES2703552T3 (es)	2019-03-11
LT2585470T (lt)	2017-04-10
UA111272C2 (uk)	2016-04-11
HUE042165T2 (hu)	2019-06-28
IL232382A0 (en)	2014-06-30
RS58265B1 (sr)	2019-03-29
RU2598852C2 (ru)	2016-09-27
EP2975042A1 (en)	2016-01-20
AR081978A1 (es)	2012-10-31
US9345719B2 (en)	2016-05-24
MY162132A (en)	2017-05-31
RU2014147193A (ru)	2015-07-10
DK2585470T3 (en)	2017-04-10
TR201821217T4 (tr)	2019-01-21
KR101589114B1 (ko)	2016-01-29
SG186378A1 (en)	2013-01-30
ES2622138T3 (es)	2017-07-05
CN105061438A (zh)	2015-11-18
NZ627709A (en)	2014-12-24
PH12012502431B1 (en)	2019-08-23
JP2014159473A (ja)	2014-09-04
HRP20170456T1 (hr)	2017-05-19
MY174196A (en)	2020-03-13
BR122014012788B1 (pt)	2022-04-19
US20130116213A1 (en)	2013-05-09
NZ605988A (en)	2014-11-28
CN105061438B (zh)	2017-07-04
RS55783B1 (sr)	2017-07-31
RU2585177C2 (ru)	2016-05-27
TW201443059A (zh)	2014-11-16
EP2585470A2 (en)	2013-05-01
IL232382A (en)	2016-12-29
TW201204364A (en)	2012-02-01
WO2011162515A3 (en)	2012-05-03
TWI513701B (zh)	2015-12-21
DK2975042T3 (en)	2019-01-21
KR101587506B1 (ko)	2016-01-25
EP2585470B1 (en)	2017-01-25
UA108889C2 (uk)	2015-06-25
PL2975042T3 (pl)	2019-07-31
AU2011269989B2 (en)	2014-12-11
USRE46511E1 (en)	2017-08-15
KR20140060473A (ko)	2014-05-20
LT2975042T (lt)	2019-01-25
SI2975042T1 (sl)	2019-02-28
HRP20190012T1 (hr)	2019-02-22
AU2011269989A8 (en)	2013-02-28
PH12012502431A1 (en)	2013-07-08
US20150045324A1 (en)	2015-02-12
WO2011162515A2 (en)	2011-12-29
BR122014012788A2 (pt)	2019-08-13
JP5834347B2 (ja)	2015-12-16
US20160229868A1 (en)	2016-08-11
BR112012033253A2 (pt)	2016-11-22
CY1118750T1 (el)	2017-07-12
HUE032515T2 (en)	2017-09-28
MX2012014601A (es)	2013-02-21
PL2585470T3 (pl)	2017-07-31
EP2585470A4 (en)	2014-01-01
CA2803056C (en)	2017-05-16
CN102947316A (zh)	2013-02-27
MX342164B (es)	2016-09-19
JP5852173B2 (ja)	2016-02-03
EP2975042B1 (en)	2018-10-03
KR20110139653A (ko)	2011-12-29
CN102947316B (zh)	2016-08-10
AR096075A2 (es)	2015-12-02
US8957065B2 (en)	2015-02-17
IL223689A (en)	2017-03-30
ZA201209742B (en)	2014-03-26
AU2011269989A1 (en)	2013-02-07
PT2975042T (pt)	2019-01-11
PT2585470T (pt)	2017-03-06
JP2013529630A (ja)	2013-07-22
TWI528962B (zh)	2016-04-11
RU2013102881A (ru)	2014-07-27

Publication	Publication Date	Title
HRP20190012T1 (hr)	2019-02-22	Novi fuzionirani pirimidin derivati za inhibiciju aktivnosti tirozin kinaze
HK1186186A1 (en)	2014-03-07	Inhibitors of brutons tyrosine kinase
IL213906A0 (en)	2011-07-31	Pyrimidinecarboxamide derivatives as inhibitors of syk kinase
HK1194381A1 (en)	2014-10-17	Inhibitors of brutons tyrosine kinase
HK1205431A1 (en)	2015-12-18	Solid forms of an epidermal growth factor receptor kinase inhibitor
HK1197060A1 (en)	2015-01-02	Inhibitors of brutons tyrosine kinase
ZA201303614B (en)	2014-11-26	Quinazolin-4(3h)-one derivatives used as p13 kinase inhibitors
ZA201309702B (en)	2015-01-28	Inhibitors of lrrk2 kinase activity
EP2593462A4 (en)	2014-07-09	NEW CONDENSED HETEROCYCLIC DERIVATIVES SUITABLE AS C-MET TYROSINE KINASE HEMMER
IL218543A0 (en)	2012-05-31	Pyrimidine derivatives as protein tyrosine kinase 2 inhibitors
HK1198168A1 (en)	2015-03-13	Aminopyrimidine derivatives for use as modulators of kinase activity
ZA201201978B (en)	2013-12-23	Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
ZA201500471B (en)	2016-10-26	Crystalline form i of tyrosine kinase inhibitor dimaleate and preparation methods thereof
IL218790A0 (en)	2012-06-28	Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
HK1200816A1 (en)	2015-08-14	Inhibitors of brutons tyrosine kinase
ZA201207482B (en)	2013-09-25	Inhibitors of protein tyrosine kinase activity
EP2754659A4 (en)	2015-08-26	4-SUBSTITUTED- (3-SUBSTITUTED-1H-PYRAZOLE-5-AMINO) -PYRIMIDINES DERIVATIVES HAVING PROTEIN KINASE INHIBITION ACTIVITY AND USE THEREOF
AU2013201520B9 (en)	2016-03-10	Solid forms of an epidermal growth factor receptor kinase inhibitor
IL244032B (en)	2018-03-29	Intermediates for the preparation of pyrazolylquinoxaline kinase inhibitors